Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemoglobin switching and its clinical implications

C A Blau1, G Stamatoyannopoulos

  • 1University of Washington, Seattle, USA.

Current Opinion in Hematology
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population structure of modern-day Italians reveals patterns of ancient and archaic ancestries in Southern Europe.

Science advances·2019
Same author

De novo mutations producing unstable hemoglobins or hemoglobins M : I. Establishment of a Depository and use of data to test for an association of de novo mutation with advanced parental age.

Human genetics·2016
Same author

Evidence for the in vivo safety of insulated foamy viral vectors.

Gene therapy·2016
Same author

Evaluating surface erythropoietin receptor in multiple myeloma.

Leukemia·2012
Same author

Using gene transfer to circumvent off-target effects.

Gene therapy·2008
Same author

Prospects for developing a molecular cure for thalassemia.

Hematology (Amsterdam, Netherlands)·2005
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Understanding hemoglobin switching offers new treatments for beta thalassemia and sickle cell disease. Research focuses on restoring fetal hemoglobin or introducing healthy globin genes to correct defects.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Hemoglobin switching is a developmental process where gamma-globin genes (fetal) are replaced by beta-globin genes (adult).
  • Beta thalassemia and sickle cell disease result from defective beta-globin gene production.
  • This process is crucial for understanding and treating globinopathies.

Purpose of the Study:

  • To review recent advances in understanding globin gene regulation.
  • To highlight novel therapeutic interventions for hemoglobinopathies based on this understanding.
  • To discuss strategies for manipulating hemoglobin switching for treatment.

Main Methods:

  • Review of current scientific literature on hemoglobin gene regulation.
  • Analysis of therapeutic strategies targeting globin gene expression.

Related Experiment Videos

  • Summary of clinical investigations into novel treatments.

    • Main Results:

    • Progress in understanding globin gene regulation has enabled new therapeutic approaches.
    • Strategies include reversing hemoglobin switching to re-establish fetal hemoglobin synthesis.
    • Gene therapy approaches aim to introduce normal exogenous globin genes.

    Conclusions:

    • Advances in hemoglobin switching research are leading to promising clinical treatments.
    • Targeting globin gene regulation offers a viable strategy for treating beta thalassemia and sickle cell disease.
    • Further clinical investigation is ongoing for these novel therapeutic interventions.